Table 1 Baseline clinical and demographic characteristics of psoriatic arthritis patients, psoriasis patients and healthy donors a
From: Th17 and Th22 cells in psoriatic arthritis and psoriasis
Patient characteristics | Psoriatic arthritis (N= 11) | Psoriasis (N= 12) | Healthy donors (N= 15) |
|---|---|---|---|
Age, mean ± SD (years) | 52 ± 17 | 51 ± 19 | 43 ± 12 |
Sex, F/M | 6/5 | 4/8 | 9/6 |
Duration of arthritis, mean ± SD (years) | 11 ± 2 | NA | NA |
Duration of psoriasis, mean ± SD (years) | 18 ± 8 | 25 ± 12 | NA |
Current treatment | Nil = 2 | Nil = 1 | Nil |
Steroids = 1 | Topical steroids = 4 | ||
Methotrexate = 4 | PUVA = 4 | ||
Sulphasalazine = 2 | Methotrexate = 1 | ||
Azathioprine = 1 | Acitretin = 2 | ||
Etanercept = 1 | Cyclosporine = 1 | ||
Adalimumab = 1 | |||
Infliximab = 1 | |||
PASI score, mean ± SD | 12 ± 6 | 13 ± 7 | 0 |
Joint count, mean ± SD | 5 ± 13 | NA | 0 |